EUVIMEDEUVIMED entdecken
Crossref

Treatment of Triple Negative Breast Cancer Using RNA-based Nanotherapeutics

Poojan Patel, Karan Mediratta, Lisheng Wang

University of Ottawa Science Undergraduate Research Journal · 17.06.2026 · 5 (2)

DOI: 10.18192/osurj.v5i2.8056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift University of Ottawa Science Undergraduate Research Journal, online erschienen am 17.06.2026. Verfasst von Poojan Patel und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive and therapeutically challenging subtype of breast cancer, accounting for a disproportionate number of breast cancer–related deaths. The absence of ER, PR) and HER2 receptors limits targeted treatment options, leaving chemotherapy as the primary therapeutic strategy. However, chemotherapy is often associated with significant toxicity, rapid development of drug resistance, and tumour recurrence due to the enrichment of cancer stem cells (CSCs). These CSCs exist in interconvertible mesenchymal-like and epitheliallike states, which lead to the excessive growth of one type of CSC and disease relapse when targeting the other. This study aimed to develop and evaluate RNA-based nanotherapeutics targeting regulatory molecules involved in TNBC survival and CSC maintenance. Specifically, the roles of a specific miRNA and cancer-suppressive mRNA were investigated for their potential to suppress oncogenic signaling and reduce CSC populations. RNA-loaded nanoparticles were prepared and characterized to enable efficient delivery into TNBC cells. The efficacy of these RNA-nanoparticles was assessed through multiple in vitro approaches. Gene expression changes were quantified using RT-qPCR, while protein-level and CSCassociated markers, including CD44 and ALDH, were analyzed using flow cytometry. Bulk tumor cell viability was assessed by MTT and PrestoBlue. It is expected that RNA-nanotherapeutics will reduce both bulk TNBC cell viability and CSCassociated phenotypes, thereby limiting tumour progression and recurrence. This work aims to contribute to the development of targeted therapies for TNBC by addressing “undruggable targets through RNA-based approaches to reduce CSC-driven resistance.

Zitieren

APA

Patel, P., Mediratta, K., & Wang, L. (2026). Treatment of Triple Negative Breast Cancer Using RNA-based Nanotherapeutics. University of Ottawa Science Undergraduate Research Journal, 5(2). https://doi.org/10.18192/osurj.v5i2.8056

Vancouver

Patel P, Mediratta K, Wang L. Treatment of Triple Negative Breast Cancer Using RNA-based Nanotherapeutics. University of Ottawa Science Undergraduate Research Journal. 2026;5(2). doi:10.18192/osurj.v5i2.8056

BibTeX
@article{Patel2026,
  author = {Patel, Poojan and Mediratta, Karan and Wang, Lisheng},
  title = {Treatment of Triple Negative Breast Cancer Using RNA-based Nanotherapeutics},
  journal = {University of Ottawa Science Undergraduate Research Journal},
  year = {2026},
  volume = {5},
  number = {2},
  doi = {10.18192/osurj.v5i2.8056}
}
Kostenlos starten →